July 2, 2015 in News from Our Companies

Rimidi named ‘Startup to Watch’

Post placeholder image
http://atdc.org/companies/rimidi-diabetes/
Dr. Lucienne Ide is co-founder and chief executive of Atlanta-based Rimidi.

The Georgia Pharmacy Association (GPhA) named Rimidi, an ATDC Select Company, one of its Five Georgia-Based Healthcare Startups to Watch For.

As part of the selection, Dr. Lucienne Ide, Rimidi’s CEO, will participate in a “Shark Tank-like” panel with four other health care startups on Sat., July 11 at the Georgia Pharmacy Convention 2015 on Amelia Island in Florida.

“We’re delighted to be selected as one of five Georgia health care companies to watch,” Ide said in a statement. “Our technology, Diabetes+Me, is being used by pharmacists to help provide care, increase patient engagement and reduce costs. I’m looking forward to sharing our latest data and receiving feedback.”

The Diabetes+Me technology provides a cloud-based platform for diabetes management. Patients can track their health and lifestyle data, as well as obtain medical and nutritional information about their condition. Health care providers can leverage the data through proprietary analytics that drive targeted decision-making for treatment options, population management, and improved care.

“We’re excited to have selected Dr. Ide for the Five Georgia Startups to Watch For panel,” Phillip Ratliff, GPhA’s vice president of communication and engagement said, in a statement. “Dr. Ide and her Diabetes+Me program epitomize the sort of forward-looking, entrepreneurial spirit we’re all about at the Georgia Pharmacy Association. It’s an honor to have her join our fantastic line-up of selected presenters.”

The Diabetes+Me technology is currently in the test-pilot phase at Desert Oasis Healthcare in Palm Springs, Calif., an affiliated medical group of the Heritage Provider Network and Heritage ACO. The Medication Management Department is conducting a study of two groups: one treated with the standard of care with the pharmacist and the other treated with the standard of care with the pharmacist combined with the Rimidi application.

The goal of the study is to test the software’s ability to lower diabetic patients’ A1C levels, improve their engagement, and enhance the clinic’s efficiency in providing quality diabetes care. The results also will be reviewed to study whether the technology helps the pharmacist’s decision-making in adjusting medications according to a patient’s individual needs. Initial results have found that using the Diabetes+Me app combined with the pharmacist’s care reduces A1C levels by more than 2 percent and increases patient satisfaction compared to the group that didn’t receive the app, according to DOHC.

Earlier this year, Rimidi announced an investment from Cox Enterprises to expand its efforts into other markets, including retail pharmacies, medical clinics and employee wellness.




By browsing this website, you agree to our privacy policy.
I Agree